Anti-TNF-α therapies have been successfully introduced for the treatment of several autoimmune diseases, including rheumatoid arthritis and Crohn’s disease, possibly suggesting the role of the TNF-α-mediated ablation of tolerogenic cDCs in these autoimmune responses [123]. The gene discussed is TNF; the disease is rheumatoid arthritis.